Gill Little
Research Subjects
Gill Little has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
James Reif
Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA
1 shared publicationJason Rossi
Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA
1 shared publicationLinli He
Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA
1 shared publicationMelanie Marguerit
Selcia Ltd., Fyfield Business & Research Park, Fyfield Road, Ongar, Essex, CM 0GS, UK, http://www.selcia.com
1 shared publicationRenee Roemmele
Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA
1 shared publicationRoger Bakale
Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA
1 shared publication
Latest Publications
- 13 November 2015
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2015 (36) , 8003-8010
Total Synthesis of [14C]‐Labelled Homoharringtonine
A total synthesis of enantiomerically pure [14C]‐labelled (–)‐homoharringtonine in 17 steps is reported. This synthetic process enabled the production of Good Manufacturing Practice (GMP) compliant (–)‐[14C]homoharringtonine that was used in a human mass balance study that was a post‐approval commitment to the U.S. Food and Drug Administration. (–)‐Homoharringtonine, also called omacetaxine mepesuccinate, is approved to treat adult patients with chronic myeloid leukemia (CML), a blood and bone marrow disease. In November 2012, the product was commercialised as Synribo® in the U.S., marketed by Teva Pharmaceuticals.
- 13 November 2015
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2015 (36) , 8003-8010
Total Synthesis of [14C]‐Labelled Homoharringtonine
A total synthesis of enantiomerically pure [14C]‐labelled (–)‐homoharringtonine in 17 steps is reported. This synthetic process enabled the production of Good Manufacturing Practice (GMP) compliant (–)‐[14C]homoharringtonine that was used in a human mass balance study that was a post‐approval commitment to the U.S. Food and Drug Administration. (–)‐Homoharringtonine, also called omacetaxine mepesuccinate, is approved to treat adult patients with chronic myeloid leukemia (CML), a blood and bone marrow disease. In November 2012, the product was commercialised as Synribo® in the U.S., marketed by Teva Pharmaceuticals.